Rheumatologist and Dermatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant (baricitinib), a JAK1/2 inhibitor (I4V-MC-B025)First published 04/10/2021 Last updated 21/05/2024 EU PAS number: EUPAS43239StudyOngoing